[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
D002648:Child; D003029:Coagulants / Q000627:therapeutic use*; D004341:Drug Evaluation; D005164:Factor IX / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D015949:Factor IXa; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male
D003029:Coagulants; D005169:Factor VIII; D005164:Factor IX; D015949:Factor IXa